{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:08:07Z","timestamp":1788815287942,"version":"build-2803163510"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","award":["ANRF\/PAIR\/2025\/000029\/PAIR"],"award-info":[{"award-number":["ANRF\/PAIR\/2025\/000029\/PAIR"]}],"id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/FST\/LS-1\/2019\/598"],"award-info":[{"award-number":["SR\/FST\/LS-1\/2019\/598"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/PURSE\/2023\/220(C)"],"award-info":[{"award-number":["SR\/PURSE\/2023\/220(C)"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118331","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:30:31Z","timestamp":1786059031000},"page":"118331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Overcoming immune resistance through tumor microenvironment reprogramming: Emerging immunotherapeutic strategies and translational advances"],"prefix":"10.1016","volume":"253","author":[{"given":"Vivek","family":"Uttam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9103-6936","authenticated-orcid":false,"given":"Sia","family":"Daffara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-1270","authenticated-orcid":false,"given":"Sandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-7993","authenticated-orcid":false,"given":"Ravneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-8475","authenticated-orcid":false,"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aklank","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111742","article-title":"Global burden, trends, and attributable risk factors of women's cancers with projection to 2050: Results from the GLOBOCAN 2022 and global burden of disease study 2021","volume":"52","author":"Wei","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0010","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bpobgyn.2015.02.008","article-title":"Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging","volume":"29","author":"Kumar","year":"2015","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161210789941847","article-title":"Recent advances in cancer therapy: an overview","volume":"16","author":"Urruticoechea","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104463","article-title":"Gynecologic cancers in 2025: a year in review","volume":"36","author":"Arenhardt","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: a great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118331_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104740","article-title":"PD-1\/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: synergistic mechanisms and research progress","volume":"211","author":"Xu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00262-024-03919-8","article-title":"Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification","volume":"74","author":"Hattori","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2026.118331_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116498","article-title":"Gynecological cancer tumor microenvironment: unveiling cellular complexity and therapeutic potential","volume":"229","author":"Garg","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118331_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117194","article-title":"Transforming the \u201ccold\u201d tumors to \u201chot\u201d tumors: strategies for immune activation","volume":"241","author":"Kong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118331_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106517","article-title":"Estrogen receptor regulation of the immune microenvironment in breast cancer","volume":"240","author":"McGuinness","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118331_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1763091","article-title":"Does immunotherapy hold great promise in endometrial cancer care?","volume":"17","author":"Braszka","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0065","article-title":"HPV infection and the immune microenvironment in cervical cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0070","doi-asserted-by":"crossref","unstructured":"A.A. Patel, Recent advances in immunotherapy in cancer treatment, Cell Mol Biol (Noisy-le-grand) 70(5) (2024) 89-99. https:\/\/doi.org\/10.14715\/cmb\/2024.70.5.13.","DOI":"10.14715\/cmb\/2024.70.5.13"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10616-024-00677-4","article-title":"Docetaxel treatment together with CTLA-4 knockdown enhances reduction of cell viability and amplifies apoptosis stimulation of MCF-7 breast cancer cells","volume":"77","author":"Hosseinkhani","year":"2025","journal-title":"Cytotechnology"},{"key":"10.1016\/j.bcp.2026.118331_b0080","first-page":"1","article-title":"Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer","volume":"42","author":"Dixon-Douglas","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bcp.2026.118331_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114712","article-title":"Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies","volume":"162","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00280-023-04506-x","article-title":"PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials","volume":"91","author":"Li","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0095","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.118331_b0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118331_b0110","doi-asserted-by":"crossref","unstructured":"N. Yanaihara, K.Y. Tse, S.J. Lee, J.G. Yoo, S. Wilailak, Immune checkpoint inhibitors in gynecologic oncology: current status and perspectives, Int. J. Gynaecol. Obstet. 171 (Suppl 1) (2025) 166-188. https:\/\/doi.org\/10.1002\/ijgo.70280.","DOI":"10.1002\/ijgo.70280"},{"key":"10.1016\/j.bcp.2026.118331_b0115","article-title":"Comprehensive evaluation of prophylactic HPV vaccines: a systematic review and meta-analysis of efficacy, safety, and immunogenicity in males and females","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/GCO.0000000000000760","article-title":"Cell-based immunotherapies in gynecologic cancers","volume":"34","author":"Lang","year":"2022","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0125","doi-asserted-by":"crossref","first-page":"27836","DOI":"10.1038\/s41598-024-79149-w","article-title":"Prognostic and immune correlation of IDO1 promoter methylation in breast cancer","volume":"14","author":"Ding","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118331_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217182","article-title":"Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer","volume":"600","author":"Gu","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00438-024-02146-1","article-title":"EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer","volume":"299","author":"Zhang","year":"2024","journal-title":"Mol. Genet. Genomics"},{"key":"10.1016\/j.bcp.2026.118331_b0140","article-title":"Immune-excluded and immune-suppressive tumor microenvironments: mechanisms, spatial biomarkers, and therapeutic rewiring","volume":"16","author":"Wang","year":"2026","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0145","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol33010048","article-title":"Advances in screening, immunotherapy, targeted agents, and precision surgery in cervical cancer: a comprehensive clinical review (2018-2025)","volume":"33","author":"Nagdev","year":"2026","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","article-title":"Current and future immunotherapy for breast cancer","volume":"17","author":"Heater","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/imcb.12250","article-title":"Cancer immunotherapy: advances and future challenges","volume":"97","author":"Macri","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118331_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0170","article-title":"Terminally exhausted CD8(+) T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218359","article-title":"Emerging biomarkers in melanoma: bridging molecular discovery and precision oncology","volume":"645","author":"Xu","year":"2026","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/JLB.3MIR0320-475R","article-title":"The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance","volume":"108","author":"Chang","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118331_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009404","article-title":"Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24020974","article-title":"Application of immune checkpoint inhibitors in gynecological cancers: what do gynecologists need to know before using immune checkpoint inhibitors?","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118331_b0195","doi-asserted-by":"crossref","unstructured":"B. Mollavelioglu, E. Cetin Aktas, N. Cabioglu, A. Abbasov, S. Onder, S. Emiroglu, M. Tukenmez, M. Muslumanoglu, A. Igci, G. Deniz, V. Ozmen, High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer, World J. Surg. Oncol. 20(1) (2022) 349. https:\/\/doi.org\/10.1186\/s12957-022-02810-z.","DOI":"10.1186\/s12957-022-02810-z"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118331_b0205","article-title":"PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2017.09.050","article-title":"PD-1 pathway and its clinical application: a 20year journey after discovery of the complete human PD-1 gene","volume":"638","author":"Berger","year":"2018","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-022-10404-x","article-title":"PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers","volume":"23","author":"Alwosaibai","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13000-020-00977-1","article-title":"Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy","volume":"15","author":"Liang","year":"2020","journal-title":"Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0225","doi-asserted-by":"crossref","first-page":"16662","DOI":"10.1038\/s41598-019-52944-6","article-title":"Clinicopathological values of PD-L1 expression in HER2-positive breast cancer","volume":"9","author":"Kurozumi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118331_b0230","doi-asserted-by":"crossref","unstructured":"P. Schmid, S. Adams, H.S. Rugo, A. Schneeweiss, C.H. Barrios, H. Iwata, V. Dieras, R. Hegg, S.A. Im, G. Shaw Wright, V. Henschel, L. Molinero, S.Y. Chui, R. Funke, A. Husain, E.P. Winer, S. Loi, L.A. Emens, I.M.T. Investigators, Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, N Engl J Med 379(22) (2018) 2108-2121. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","DOI":"10.1056\/NEJMoa1809615"},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0235","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/bjs\/znab103","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis","volume":"108","author":"Davey","year":"2021","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.bcp.2026.118331_b0240","doi-asserted-by":"crossref","unstructured":"I. Melero, D.M. Berman, M.A. Aznar, A.J. Korman, J.L. Perez Gracia, J. Haanen, Evolving synergistic combinations of targeted immunotherapies to combat cancer, Nat. Rev. Cancer 15(8) (2015) 457-72. https:\/\/doi.org\/10.1038\/nrc3973.","DOI":"10.1038\/nrc3973"},{"key":"10.1016\/j.bcp.2026.118331_b0245","article-title":"Molecular and clinical characterization of LAG3 in breast cancer through 2994 samples","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0250","doi-asserted-by":"crossref","unstructured":"I.M. Yasinska, S.S. Sakhnevych, L. Pavlova, A. Teo Hansen Selno, A.M. Teuscher Abeleira, O. Benlaouer, I. Goncalves Silva, M. Mosimann, L. Varani, M. Bardelli, R. Hussain, G. Siligardi, D. Cholewa, S.M. Berger, B.F. Gibbs, Y.A. Ushkaryov, E. Fasler-Kan, E. Klenova, V.V. Sumbayev, The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer, Front Immunol 10 (2019) 1594. https:\/\/doi.org\/10.3389\/fimmu.2019.01594.","DOI":"10.3389\/fimmu.2019.01594"},{"issue":"12","key":"10.1016\/j.bcp.2026.118331_b0255","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118331_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235757","article-title":"The dual blockade of the TIGIT and PD-1\/PD-L1 pathway as a new hope for ovarian cancer patients","volume":"14","author":"Pawlowska","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bcp.2026.118331_b0265","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-017-2031-x","article-title":"Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions","volume":"66","author":"Xu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"18","key":"10.1016\/j.bcp.2026.118331_b0270","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-25-2286","article-title":"A new VISTA in intracellular checkpoint signaling in triple-negative breast cancer","volume":"85","author":"Tao","year":"2025","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0275","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0280","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"Laubli","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2026.118331_b0285","article-title":"The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer","volume":"81","author":"Wang","year":"2025","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.bcp.2026.118331_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102713","article-title":"Targeting Siglec-15 mediates mitochondrial retrograde regulation of cervical cancer development","volume":"93","author":"Wang","year":"2025","journal-title":"Tissue Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0295","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ygyno.2017.05.003","article-title":"Immunotherapy for gynecological cancers: opportunities abound","volume":"145","author":"Nelson","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1762619","article-title":"Overcoming immune resistance in ovarian cancer: checkpoint inhibitors, tumor microenvironment, and translational advances","volume":"16","author":"Yue","year":"2026","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118331_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172940","article-title":"Unlocking the potential of immune checkpoint inhibitors in HR+\/HER2- breast cancer: a systematic review","volume":"17","author":"Di Grazia","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0310","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1186\/s12885-024-13058-z","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118331_b0315","doi-asserted-by":"crossref","unstructured":"J. Cortes, D.W. Cescon, H.S. Rugo, Z. Nowecki, S.A. Im, M.M. Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, E. Holgado, H. Iwata, N. Masuda, M.T. Otero, E. Gokmen, S. Loi, Z. Guo, J. Zhao, G. Aktan, V. Karantza, P. Schmid, K.-. Investigators, Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, Lancet 396(10265) (2020) 1817-1828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","DOI":"10.1200\/JCO.2020.38.15_suppl.1000"},{"key":"10.1016\/j.bcp.2026.118331_b0320","doi-asserted-by":"crossref","unstructured":"P. Schmid, J. Cortes, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, P.A. Fasching, F. Cardoso, M. Untch, L. Jia, V. Karantza, J. Zhao, G. Aktan, R. Dent, J. O'Shaughnessy, K.-. Investigators, Pembrolizumab for early triple-negative breast cancer, N Engl. J. Med. 382(9) (2020) 810-821. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","DOI":"10.1056\/NEJMoa1910549"},{"issue":"17","key":"10.1016\/j.bcp.2026.118331_b0325","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0330","doi-asserted-by":"crossref","unstructured":"N. Colombo, C. Dubot, D. Lorusso, M.V. Caceres, K. Hasegawa, R. Shapira-Frommer, K.S. Tewari, P. Salman, E. Hoyos Usta, E. Yanez, M. Gumus, M. Olivera Hurtado de Mendoza, V. Samouelian, V. Castonguay, A. Arkhipov, S. Toker, K. Li, S.M. Keefe, B.J. Monk, K.-. Investigators, Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer, N Engl J Med 385(20) (2021) 1856-1867. https:\/\/doi.org\/10.1056\/NEJMoa2112435.","DOI":"10.1056\/NEJMoa2112435"},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0335","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.3802\/jgo.2025.36.e110","article-title":"Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis","volume":"36","author":"Kim","year":"2025","journal-title":"J. Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0340","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0345","first-page":"499","article-title":"Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells","volume":"21","author":"Fang","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bcp.2026.118331_b0350","doi-asserted-by":"crossref","unstructured":"I. Siddiqui, K. Schaeuble, V. Chennupati, S.A. Fuertes Marraco, S. Calderon-Copete, D. Pais Ferreira, S.J. Carmona, L. Scarpellino, D. Gfeller, S. Pradervand, S.A. Luther, D.E. Speiser, W. Held, Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy, Immunity 50(1) (2019) 195-211 e10. https:\/\/doi.org\/10.1016\/j.immuni.2018.12.021.","DOI":"10.1016\/j.immuni.2018.12.021"},{"issue":"9","key":"10.1016\/j.bcp.2026.118331_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092234","article-title":"The potential of tissue-resident memory T cells for adoptive immunotherapy against cancer","volume":"10","author":"Beumer-Chuwonpad","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118331_b0360","article-title":"Tissue-resident immune cells in cervical cancer: emerging roles and therapeutic implications","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0365","doi-asserted-by":"crossref","first-page":"C167","DOI":"10.1152\/ajpcell.00151.2022","article-title":"Physiology of chemokines in the cancer microenvironment","volume":"324","author":"Drouillard","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"19","key":"10.1016\/j.bcp.2026.118331_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194800","article-title":"Heterogeneity and functions of tumor-infiltrating antibody secreting cells: lessons from breast, ovarian, and other solid cancers","volume":"14","author":"Lounici","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118331_b0375","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2026.118331_b0380","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102655","article-title":"The Value of CXCL1, CXCL2, CXCL3, and CXCL8 as potential prognosis markers in cervical cancer: evidence of E6\/E7 from HPV16 and 18 in chemokines regulation","volume":"11","author":"Fernandez-Avila","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0385","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2016.172","article-title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer","volume":"115","author":"Bronger","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"6824","key":"10.1016\/j.bcp.2026.118331_b0390","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Muller","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0395","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-026-02126-2","article-title":"CXCL12-mediated T cell infiltration drives breast cancer metastasis","volume":"26","author":"Liu","year":"2026","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0400","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-026-00893-5","article-title":"Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer","volume":"12","author":"Ye","year":"2026","journal-title":"npj Breast Cancer"},{"issue":"7577","key":"10.1016\/j.bcp.2026.118331_b0405","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bcp.2026.118331_b0410","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41416-024-02677-9","article-title":"Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses","volume":"130","author":"Kment","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0415","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI37480","article-title":"Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer","volume":"119","author":"Bierie","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0420","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bcp.2026.118331_b0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295684","article-title":"Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs","volume":"14","author":"Shao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2025.104982","article-title":"Revisiting TAM polarization: beyond M1- and M2-type TAM toward clinical precision in macrophage-targeted therapy","volume":"143","author":"Wang","year":"2025","journal-title":"Exp. Mol. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0435","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/cas.70324","article-title":"Tumor-associated macrophage-derived CXCL1 promotes endometrial cancer progression through the CXCR2\/NF-kappaB pathway","volume":"117","author":"Xia","year":"2026","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0440","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution","volume":"43","author":"Yang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0445","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/1759-7714.14268","article-title":"Tumor-associated macrophages: An important player in breast cancer progression","volume":"13","author":"Huang","year":"2022","journal-title":"Thorac Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0450","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20203145","article-title":"The correlation between tumor-associated macrophage infiltration and progression in cervical carcinoma","volume":"41","author":"Guo","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bcp.2026.118331_b0455","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.2147\/OTT.S216355","article-title":"Tumor-associated macrophages (TAMs): a critical activator in ovarian cancer metastasis","volume":"12","author":"Yin","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bcp.2026.118331_b0460","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1749965","article-title":"Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies","volume":"17","author":"Dash","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0465","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-022-03226-0","article-title":"Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF\/BAFF-R pathway to promote immunosuppression in cervical cancer","volume":"72","author":"Jianyi","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051073","article-title":"Myeloid-derived suppressor cells as therapeutic targets in uterine cervical and endometrial cancers","volume":"10","author":"Mabuchi","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.bcp.2026.118331_b0475","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00262-020-02628-2","article-title":"The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer","volume":"69","author":"Komura","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0480","doi-asserted-by":"crossref","DOI":"10.1177\/1010428318776485","article-title":"Myeloid-derived suppressor cells and their role in gynecological malignancies","volume":"40","author":"Mabuchi","year":"2018","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0485","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12967-025-06896-3","article-title":"Targeting immune microenvironment in cervical cancer: current research and advances","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0490","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0495","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/13543784.2022.2067527","article-title":"PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers","volume":"31","author":"Luo","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bcp.2026.118331_b0500","article-title":"Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0505","article-title":"Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40364-021-00312-w","article-title":"Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment","volume":"9","author":"Chen","year":"2021","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0515","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0520","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118331_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217072","article-title":"CD39 transforming cancer therapy by modulating tumor microenvironment","volume":"597","author":"Xu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118331_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1101433","article-title":"Lactate exposure shapes the metabolic and transcriptomic profile of CD8+ T cells","volume":"14","author":"Barbieri","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0535","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00262-023-03382-x","article-title":"Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer","volume":"72","author":"Wang","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"66","key":"10.1016\/j.bcp.2026.118331_b0540","doi-asserted-by":"crossref","first-page":"110426","DOI":"10.18632\/oncotarget.22786","article-title":"Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.bcp.2026.118331_b0545","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.7150\/jca.81099","article-title":"NOX4-derived ROS regulates aerobic glycolysis of breast cancer through YAP pathway","volume":"14","author":"Zhang","year":"2023","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0550","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12944-022-01651-9","article-title":"Identification of a novel lipid metabolism-related gene signature within the tumour immune microenvironment for breast cancer","volume":"21","author":"Chang","year":"2022","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.bcp.2026.118331_b0555","article-title":"A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0560","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12967-021-03057-0","article-title":"Establishment of a novel glycolysis-related prognostic gene signature for ovarian cancer and its relationships with immune infiltration of the tumor microenvironment","volume":"19","author":"Bi","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118331_b0565","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2024.02.004","article-title":"GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15","volume":"185","author":"Chang","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0570","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/ol.2024.14772","article-title":"SLC7A5 regulates tryptophan uptake and PD\u2011L1 expression levels via the kynurenine pathway in ovarian cancer","volume":"29","author":"Jiang","year":"2025","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0575","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/JLB.3A0718-274RR","article-title":"Lactate secreted by cervical cancer cells modulates macrophage phenotype","volume":"105","author":"Stone","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2026.118331_b0580","doi-asserted-by":"crossref","unstructured":"I.C. Iser, P. de Andrade Mello, S. Davies, J.F. de Souza Santos, D.A. Pilger, A. Buffon, A.P.S. Bertoni, M.R. Wink, A three-dimensional microenvironment alters CD73 expression in cervical cancer, Cell Biochem Funct 39(6) (2021) 780-790. https:\/\/doi.org\/10.1002\/cbf.3649.","DOI":"10.1002\/cbf.3649"},{"key":"10.1016\/j.bcp.2026.118331_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1384778","article-title":"Correlation study of serum lipid levels and lipid metabolism-related genes in cervical cancer","volume":"14","author":"Cheng","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118331_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30746","article-title":"Cervical cancer subtype identification and model building based on lipid metabolism and post-infection microenvironment immune landscape","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bcp.2026.118331_b0595","article-title":"Lactate dehydrogenase A is a diagnostic biomarker associated with immune infiltration, m6A modification and ferroptosis in endometrial cancer","volume":"14","author":"Huang","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0600","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s12885-023-10934-y","article-title":"Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer","volume":"23","author":"Shi","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118331_b0605","article-title":"Comprehensive analysis of the glycolysis-related gene prognostic signature and immune infiltration in endometrial cancer","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118331_b0610","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953115","article-title":"Targeting immunometabolism mediated by the IDO1 pathway: a new mechanism of immune resistance in endometrial cancer","volume":"13","author":"Passarelli","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118331_b0615","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41379-018-0039-1","article-title":"Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas","volume":"31","author":"Mills","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bcp.2026.118331_b0620","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84508","article-title":"The CD73 immune checkpoint promotes tumor cell metabolic fitness","volume":"12","author":"Allard","year":"2023","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.bcp.2026.118331_b0625","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1633235","article-title":"Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy","volume":"8","author":"Verdura","year":"2019","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.bcp.2026.118331_b0630","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1097\/JS9.0000000000001582","article-title":"Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer","volume":"110","author":"Li","year":"2024","journal-title":"Int. J. Surg."},{"issue":"22","key":"10.1016\/j.bcp.2026.118331_b0635","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213937","article-title":"Statins as repurposed drugs in gynecological cancer: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0640","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41401-025-01639-y","article-title":"DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I\/MDA5-MAVS to enhance antitumor immunity","volume":"47","author":"Tu","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0645","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0650","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","article-title":"Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade","volume":"38","author":"Qin","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0655","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s12672-025-02630-z","article-title":"DNA methylation and transcription factor-driven immune subtypes in ovarian cancer","volume":"16","author":"Hu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0660","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0665","first-page":"2655","article-title":"Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim\u20113 and galectin\u20119, in cervical cancer","volume":"42","author":"Zhang","year":"2019","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0670","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1038\/s41598-022-11415-1","article-title":"ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer","volume":"12","author":"Yang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118331_b0675","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5119411","article-title":"Integrated bioinformatic analysis of DNA methylation and immune infiltration in endometrial cancer","volume":"2022","author":"Dai","year":"2022","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bcp.2026.118331_b0680","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3815853","article-title":"IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING","volume":"2022","author":"Zeng","year":"2022","journal-title":"J. Immunol. Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118331_b0685","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16111999","article-title":"Evaluation of ARID1A as a potential biomarker for predicting response to immune checkpoint inhibitors in patients with endometrial cancer","volume":"16","author":"Yamashita","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0690","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s43556-025-00373-5","article-title":"Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications","volume":"6","author":"Ma","year":"2025","journal-title":"Mol Biomed"},{"issue":"18","key":"10.1016\/j.bcp.2026.118331_b0695","doi-asserted-by":"crossref","first-page":"19022","DOI":"10.1021\/acs.jmedchem.5c01092","article-title":"Design, Synthesis, and biological evaluation of quinoline-based hydroxamic acid derivatives as dual DNMT and HDAC inhibitors with potent anti-breast cancer activity","volume":"68","author":"Lin","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0700","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","author":"Moufarrij","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118331_b0705","doi-asserted-by":"crossref","unstructured":"M.K. Sundaram, M.Z. Ansari, A. Al Mutery, M. Ashraf, R. Nasab, S. Rai, N. Rais, A. Hussain, Genistein Induces alterations of epigenetic modulatory signatures in human cervical cancer cells, Anticancer Agents Med Chem 18(3) (2018) 412-421. https:\/\/doi.org\/10.2174\/1871520617666170918142114.","DOI":"10.2174\/1871520617666170918142114"},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0710","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31071180","article-title":"Antibody-drug conjugates (ADCs): a review of structural design, technological evolution, and future perspectives","volume":"31","author":"Wu","year":"2026","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","article-title":"Antibody-drug conjugates in gynecologic cancers","volume":"25","author":"Anastasio","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b0720","first-page":"127","article-title":"Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates","volume":"9","author":"Yamaguchi","year":"2026","journal-title":"Antib Ther"},{"key":"10.1016\/j.bcp.2026.118331_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2026.102742","article-title":"Antibody-drug conjugates in breast cancer: Progress and future directions","author":"Bili Newman","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2026.118331_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218622","article-title":"From linker stability to linker fitness: redefining ADC design for clinical translation","volume":"656","author":"Ma","year":"2026","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0735","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.118331_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicolo","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2026.118331_b0745","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.118331_b0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101978","article-title":"Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets","volume":"35","author":"He","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"29","key":"10.1016\/j.bcp.2026.118331_b0755","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0760","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2024.07.002","article-title":"Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma","volume":"189","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0765","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1292211","article-title":"Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: Biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118331_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/or.2026.1781533","article-title":"Sacituzumab tirumotecan (sac-TMT\/MK-2870\/SKB264): a novel antibody-drug conjugate in breast cancer","volume":"20","author":"Sofianidi","year":"2026","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.bcp.2026.118331_b0780","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1334938","article-title":"Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"13","author":"Cheng","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0785","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","author":"Dent","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0795","article-title":"TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naive locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations","volume":"15","author":"Newsom-Davis","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0800","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-47488-5","article-title":"Deruxtecan-based antibody-drug-conjugates induce senescence in HER2-positive breast cancer","author":"Vezzoli","year":"2026","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0805","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bulcan.2023.12.011","article-title":"Sacituzumab-govitecan in hormone-receptor positive\/HER2-negative advanced breast cancer","volume":"111","author":"Besnainou","year":"2024","journal-title":"Bull. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0810","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14712598.2021.1840547","article-title":"Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan","volume":"21","author":"McGuinness","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bcp.2026.118331_b0815","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2026.02.004","article-title":"Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts","volume":"206","author":"Palmieri","year":"2026","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b0820","article-title":"Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan","volume":"1881","author":"Xie","year":"2026","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2026.118331_b0825","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejps.2016.08.015","article-title":"HER2-targeted antibody drug conjugates for ovarian cancer therapy","volume":"93","author":"Jiang","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0830","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41467-023-44533-z","article-title":"The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results","volume":"15","author":"Lewis","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b0835","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2021.08.014","article-title":"DHES0815A, a novel antibody-drug conjugate targeting HER2\/neu, is highly active against uterine serous carcinomas in vitro and in vivo","volume":"163","author":"Tymon-Rosario","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118331_b0840","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115222","article-title":"Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0845","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/15384047.2017.1395118","article-title":"In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers","volume":"19","author":"Patel","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0850","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age","volume":"17","author":"Liu","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2026.118331_b0855","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.annonc.2024.08.781","article-title":"719MO A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer","volume":"35","author":"Lee","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0860","doi-asserted-by":"crossref","unstructured":"S. Pignata, G. Scambia, C. Pisano, E. Breda, M. Di Maio, S. Greggi, G. Ferrandina, D. Lorusso, V. Zagonel, A. Febbraro, N. Riva, V. De Rosa, C. Gallo, F. Perrone, C. Multicentre Italian Trials in Ovarian, G. Gynecologic Malignancies, A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group, Br J Cancer 96(11) (2007) 1639-43. https:\/\/doi.org\/10.1038\/sj.bjc.6603787.","DOI":"10.1038\/sj.bjc.6603787"},{"issue":"7","key":"10.1016\/j.bcp.2026.118331_b0865","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0870","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-025-07402-9","article-title":"Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer","volume":"16","author":"Yao","year":"2025","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bcp.2026.118331_b0875","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.3390\/curroncol31110522","article-title":"Antibody-drug conjugates: a start of a new era in gynecological cancers","volume":"31","author":"Fasih","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0880","doi-asserted-by":"crossref","unstructured":"A.J. Grippin, C. Marconi, S. Copling, N. Li, C. Braun, C. Woody, E. Young, P. Gupta, M. Wang, A. Wu, S.D. Jeong, D. Soni, F. Weidert, C. Xie, E. Goldenberg, A. Kim, C. Zhao, A. DeVries, P. Castillo, R. Lohray, M.K. Rooney, B.R. Schrank, Y. Wang, Y. Ma, E. Chang, R. Kouzy, K. Dyson, J. Jafarnia, N. Nariman, G. Gladish, J. New, A. Argueta, D. Amaya, N. Thomas, A. Doty, J. Chen, N. Copling, G. Alatrash, J. Simon, A.B. Davies, W. Dennis, R. Liang, J. Lewis, X. Wei, W. Rinsurongkawong, A.A. Vaporciyan, A. Johns, D.C. Team, J. Lee, J.H. Lee, R. Sun, P. Sharma, H. Tran, J. Zhang, D.L. Gibbons, J. Wargo, B.Y.S. Kim, J.V. Heymach, H.R. Mendez-Gomez, W. Jiang, E.J. Sayour, S.H. Lin, SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade, Nature 647(8089) (2025) 488-497. https:\/\/doi.org\/10.1038\/s41586-025-09655-y.","DOI":"10.1016\/j.annonc.2025.09.066"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0885","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.118331_b0890","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s43018-025-01088-w","article-title":"Boosting cancer immunotherapy with COVID-19 mRNA vaccines","volume":"6","author":"Pavlaki","year":"2025","journal-title":"Nat Cancer"},{"issue":"7872","key":"10.1016\/j.bcp.2026.118331_b0895","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.bcp.2026.118331_b0900","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1158\/1078-0432.CCR-21-1579","article-title":"Immunization with a plasmid DNA vaccine encoding the N-terminus of insulin-like growth factor binding protein-2 in advanced ovarian cancer leads to high-level type I immune responses","volume":"27","author":"Cecil","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118331_b0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.01.070","article-title":"Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions","author":"Xu","year":"2026","journal-title":"J. Adv. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b0910","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.bcp.2026.118331_b0915","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovic","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118331_b0920","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118331_b0925","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1485461","article-title":"Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer","volume":"15","author":"Kutle","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b0930","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2025.10.001","article-title":"Reprogramming natural killer cells in the tumor microenvironment: Challenges and therapeutic opportunities","volume":"86","author":"Ma","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"issue":"23","key":"10.1016\/j.bcp.2026.118331_b0935","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16233918","article-title":"Advances in immunotherapy for endometrial cancer: insights into MMR status and tumor microenvironment","volume":"16","author":"Alberti-Valls","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0940","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0945","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b0950","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2025.2541517","article-title":"Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis","volume":"11","author":"Tang","year":"2025","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.bcp.2026.118331_b0955","doi-asserted-by":"crossref","unstructured":"M.R. Mirza, D.M. Chase, B.M. Slomovitz, R. dePont Christensen, Z. Novak, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L.M. Landrum, L.C. Hanker, A. Stuckey, I. Boere, M.A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M.S. Shahin, S.E. Gill, B.J. Monk, J. Buscema, T.J. Herzog, L.J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R.L. Coleman, M.A. Powell, R. Investigators, Dostarlimab for primary advanced or recurrent endometrial cancer, N. Engl. J. Med. 388(23) (2023) 2145-2158. https:\/\/doi.org\/10.1056\/NEJMoa2216334.","DOI":"10.1056\/NEJMoa2216334"},{"issue":"8","key":"10.1016\/j.bcp.2026.118331_b0960","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0965","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ygyno.2024.07.016","article-title":"Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"190","author":"Mirza","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b0970","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/j.annonc.2021.08.1262","volume":"32","author":"Mirza","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118331_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2026.118331_b0980","doi-asserted-by":"crossref","unstructured":"K.S. Tewari, N. Colombo, B.J. Monk, C. Dubot, M.V. Caceres, K. Hasegawa, R. Shapira-Frommer, P. Salman, E. Yanez, M. Gumus, M. Olivera Hurtado de Mendoza, V. Samouelian, V. Castonguay, A. Arkhipov, C. Tekin, K. Li, S. Toker, S.M. Keefe, D. Lorusso, Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial, JAMA Oncol 10(2) (2024) 185-192. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5410.","DOI":"10.1001\/jamaoncol.2023.5410"},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b0985","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s11912-025-01676-0","article-title":"Effectiveness and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review of real-world studies","volume":"27","author":"Kong","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bcp.2026.118331_b0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105312","article-title":"Immunotherapy advancements in high-grade serous ovarian cancer: from promise to practice","volume":"223","author":"Heidinger","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118331_b0995","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b1000","article-title":"Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody-drug conjugates, and clinical trial innovations","volume":"15","author":"Koshkimbayeva","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b1005","doi-asserted-by":"crossref","unstructured":"R. Shapira-Frommer, L. Mileshkin, L. Manzyuk, N. Penel, M. Burge, S.A. Piha-Paul, E. Girda, J.A. Lopez Martin, M.G.J. van Dongen, A. Italiano, L. Xu, F. Jin, K. Norwood, P.A. Ott, Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study, Gynecol Oncol 166(2) (2022) 211-218. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.029.","DOI":"10.1016\/j.ygyno.2022.01.029"},{"key":"10.1016\/j.bcp.2026.118331_b1010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2025.10.021","article-title":"Feasibility IB trial of paclitaxel\/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary","volume":"203","author":"Washington","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b1015","doi-asserted-by":"crossref","unstructured":"A.F. Agyemang, S. Lele, The Use of Immunotherapy for Treatment of Gynecologic Malignancies, in: S. Lele (Ed.), Ovarian Cancer, Brisbane (AU), 2022.","DOI":"10.36255\/exon-publications-ovarian-cancer-immunotherapy"},{"key":"10.1016\/j.bcp.2026.118331_b1020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b1025","article-title":"Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"10.1016\/j.bcp.2026.118331_b1030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.118331_b1035","first-page":"1515","article-title":"Current status of management of immune-related adverse events and practical needs for oncologist education","volume":"22","author":"Tian","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bcp.2026.118331_b1040","article-title":"Solid tumour cellular therapy - principles of toxicity management","volume":"25","author":"Julve","year":"2025","journal-title":"Immunooncol. Technol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1045","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010168","article-title":"Immunotherapy in recurrent ovarian cancer","volume":"13","author":"Chen","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118331_b1055","doi-asserted-by":"crossref","unstructured":"B.J. Monk, K.S. Tewari, C. Dubot, M.V. Caceres, K. Hasegawa, R. Shapira-Frommer, P. Salman, E. Yanez, M. Gumus, M.O. Hurtado de Mendoza, V. Samouelian, V. Castonguay, A. Arkhipov, C. Tekin, K. Li, A. Martin Nguyen, M.J. Monberg, N. Colombo, D. Lorusso, Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol 24(4) (2023) 392-402. https:\/\/doi.org\/10.1016\/S1470-2045(23)00052-9.","DOI":"10.1016\/S1470-2045(23)00052-9"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118331_b1065","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.6004\/jnccn.2020.7640","article-title":"Immune-related adverse events (irAEs): implications for immune checkpoint inhibitor therapy","volume":"18","author":"Zhou","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol Biomed"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-024-07401-y","article-title":"SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer","volume":"207","author":"Zhang","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1085","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-025-02139-6","article-title":"Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer","volume":"23","author":"Naik","year":"2025","journal-title":"Cell Commun. Signaling"},{"issue":"2","key":"10.1016\/j.bcp.2026.118331_b1090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2326-6066.CIR-24-0084","article-title":"Targeting of tumoral NAC1 mitigates myeloid-derived suppressor cell\u2013mediated immunosuppression and potentiates anti\u2013PD-1 therapy in ovarian cancer","volume":"13","author":"Dong","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1095","article-title":"NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer","volume":"23","author":"Ngule","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1100","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-026-03855-6","article-title":"Elevated GPX3 expression in endometriosis: implications for pathogenesis and immune cell infiltration","volume":"31","author":"Mao","year":"2026","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118331_b1105","doi-asserted-by":"crossref","DOI":"10.1007\/s00438-024-02146-1","article-title":"EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer","volume":"299","author":"Zhang","year":"2024","journal-title":"Mol. Genet. Genomics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b1110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3892\/br.2025.1921","article-title":"Precision medicine in gynecological cancer (Review)","volume":"22","author":"Aravantinou-Fatorou","year":"2025","journal-title":"Biomed Rep"},{"issue":"3","key":"10.1016\/j.bcp.2026.118331_b1115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10147-025-02699-0","article-title":"Recent advances in immunotherapy for cervical cancer","volume":"30","author":"Ogasawara","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118331_b1120","article-title":"Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions","volume":"16","author":"Lian","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118331_b1125","article-title":"Single-cell technologies and spatial transcriptomics: decoding immune low - response states in endometrial cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:19:13Z","timestamp":1788812353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":225,"alternative-id":["S0006295226006702"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118331","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming immune resistance through tumor microenvironment reprogramming: Emerging immunotherapeutic strategies and translational advances","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118331"}}